SRRK — Scholar Rock Holding Corp · catalysts, narrative & risks

Overview

Scholar Rock Holding Corp (SRRK, Nasdaq) is a late-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on rare neuromuscular diseases—chiefly spinal muscular atrophy (SMA)—through its anti-myostatin platform. Its lead asset, apitegromab (marketed as ISEMBYLD / apitegromab-mstn), received U.S. FDA approval in September 2026, shifting the company from a development-stage to a launch-execution narrative [6][10]. The company reports essentially zero commercial revenue and mounting net losses.